Sobi, or Swedish Orphan Biovitrum, is a specialized international biopharmaceutical company based in Stockholm. The organization focuses on developing innovative medicines aimed at transforming the lives of individuals affected by rare diseases. Sobi is engaged in ongoing research and has a pipeline of therapies under development, reflecting its commitment to addressing unmet medical needs in this area.
The company emphasizes a patient-centered approach, which is evident in its efforts to share patient experiences and stories. Sobi provides regular updates on its progress through press releases and comprehensive interim reports, ensuring transparency about its research and development activities. Additionally, the organization offers career opportunities, contributing to its global reach and operational capabilities from its dedicated head office.